Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1979 Sep;40(3):335–353. doi: 10.1038/bjc.1979.187

Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of phenytoin on the pharmacokinetics and toxicity of misonidazole in mice.

P Workman
PMCID: PMC2010042  PMID: 508562

Abstract

Concentrations of the hypoxic cell radiosensitizer misonidazole (MIS) and its O-demethylated metabolite Ro 05-9963 were determined in plasma (or blood), brain and tumour after injection of 1 g/kg MIS i.p. to control mice or mice pretreated with 4-6 daily injections of phenobarbitone or phenytoin. Analysis was by high-performance liquid chromatography (HPLC). Phenobarbitone and phenytoin did not alter the peak MIS concentration in plasma, brain or tumor. However, the apparent elimination half-life (t 1/2) for MIS was reduced by 20-67%, and the area under the curve (AUC) was decreased by 23-49% in plasma, brain and tumour. The decrease in MIS t 1/2 was associated with an initially increased Ro 05-9963 metabolite concentration. However, the AUC for total 2-nitromidazole (MIS + Ro 05-9963) in plasma, tumour and brain was reduced by 20-50%. Urinary excretion of MIS and its metabolites accounted for 15-42% of the injected dose, and was unaltered by pretreatment with phenobarbitone or phenytoin. Tumour/plasm and brain/plasma concentration ratios for MIS, and tumour/plasma ratios for Ro 05-9963 were very similar, but the brain/tumour ratios for Ro 05-9963 were considerably lower. Tissue/plasma ratios were unaltered by pretreatment with phenobarbitone or phenytoin. The acute LD50 for MIS was increased from 1.54 to 1.90 g/kg after phenobarbitone pretreatment and 1.78 g/kg after phenytoin pretreatment. In addition, pretreatment with either compound shortened the duration of the MIS-induced decrease in body temperature. These data suggest that pretreatment with microsomal-enzyme-inducing agents may reduce the toxicity of MIS without affecting the radiosensitization. The significance of these findings for the mechanism of MIS toxicity is also discussed.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. M., Yu N. Y., Workman P. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer. 1979 Mar;39(3):310–320. doi: 10.1038/bjc.1979.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Conney A. H. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967 Sep;19(3):317–366. [PubMed] [Google Scholar]
  3. Connor T. H., Stoeckel M., Evrard J., Legator M. S. The contribution of metronidazole and two metabolites to the mutagenic activity detected in urine of treated humans and mice. Cancer Res. 1977 Feb;37(2):629–633. [PubMed] [Google Scholar]
  4. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Foster J. L. Differential cytotoxic effects of metronidazole and other nitro-heterocyclic drugs against hypoxic tumour cells. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):153–156. doi: 10.1016/0360-3016(78)90131-1. [DOI] [PubMed] [Google Scholar]
  6. Gerber N., Arnold K. Studies on the metabolism of diphenylhydantoin in mice. J Pharmacol Exp Ther. 1969 May;167(1):77–90. [PubMed] [Google Scholar]
  7. Marshall W. J., McLean A. E. The effect of oral phenobarbitone on hepatic microsomal cytochrome P-450 and demethylation activity in rats fed normal and low protein diets. Biochem Pharmacol. 1969 Jan;18(1):153–157. doi: 10.1016/0006-2952(69)90020-3. [DOI] [PubMed] [Google Scholar]
  8. McNally N. J., Denekamp J., Sheldon P., Flockhart I. R., Stewart F. A. Radiosensitization by misonidazole (Ro 07-0582). The importance of timing and tumor concentration of sensitizer. Radiat Res. 1978 Mar;73(3):568–580. [PubMed] [Google Scholar]
  9. Rockwell S. C., Kallman R. F., Fajardo L. F. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst. 1972 Sep;49(3):735–749. [PubMed] [Google Scholar]
  10. Rutty C. J., Connors T. A. In vitro studies with hexamethylmelamine. Biochem Pharmacol. 1977 Dec 15;26(24):2385–2391. doi: 10.1016/0006-2952(77)90446-4. [DOI] [PubMed] [Google Scholar]
  11. Rutty C. J., Connors T. A., Nguyen-Hoang-Nam, Do-Cao-Thang, Hoellinger H. In vivo studies with hexamethylmelamine. Eur J Cancer. 1978 Jun;14(6):713–720. doi: 10.1016/0014-2964(78)90308-0. [DOI] [PubMed] [Google Scholar]
  12. Sikora K., Stern P., Lennox E. Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature. 1977 Oct 27;269(5631):813–815. doi: 10.1038/269813a0. [DOI] [PubMed] [Google Scholar]
  13. Sladek N. E., Domeyer B. E., Merriman R. L., Brophy G. T. Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly, or intraperitoneally on hepatic microsomal mixed-function oxygenase activity. Drug Metab Dispos. 1978 Jul-Aug;6(4):412–417. [PubMed] [Google Scholar]
  14. Stevenson I. H., Turnbull M. J. Hepatic drug-metabolising enzyme activity and duration of hexobarbitone anaesthesia in barbitone-dependent and withdrawn rats. Biochem Pharmacol. 1968 Nov;17(11):2297–2305. doi: 10.1016/0006-2952(68)90037-3. [DOI] [PubMed] [Google Scholar]
  15. Twentyman P. R., Bleehen N. M. Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer. 1975 Oct;32(4):491–501. doi: 10.1038/bjc.1975.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Urtasun R. C., Chapman J. D., Feldstein M. L., Band R. P., Rabin H. R., Wilson A. F., Marynowski B., Starreveld E., Shnitka T. Peripheral neuropathy related to misonidazole: incidence and pathology. Br J Cancer Suppl. 1978 Jun;3:271–275. [PMC free article] [PubMed] [Google Scholar]
  17. Wardman P. The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Curr Top Radiat Res Q. 1977 Aug;11(4):347–398. [PubMed] [Google Scholar]
  18. Warren R. D., Bender R. A. Drug interactions with antineoplastic agents. Cancer Treat Rep. 1977 Oct;61(7):1231–1241. [PubMed] [Google Scholar]
  19. Watson J. V. The cell proliferation kinetics of the EMT6/M/AC mouse tumour at four volumes during unperturbed growth in vivo. Cell Tissue Kinet. 1976 Mar;9(2):147–156. doi: 10.1111/j.1365-2184.1976.tb01262.x. [DOI] [PubMed] [Google Scholar]
  20. Whitmore G. F., Gulyas S., Varghese A. J. Sensitizing and toxicity properties of misonidazole and its derivatives. Br J Cancer Suppl. 1978 Jun;3:115–119. [PMC free article] [PubMed] [Google Scholar]
  21. Workman P., Wiltshire C. R., Plowman P. N., Bleehen N. M. Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer. 1978 Dec;38(6):709–718. doi: 10.1038/bjc.1978.277. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES